Akihiko Tanaka

Akihiko Tanaka

Auto-generated profile, based on publicly available information

Akihiko Tanaka

Division of Respiratory Medicine and Allergology, Department of Medicine, Showa Medical University School of Medicine, Showa Medical University Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2010 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
SOS. Ohta
S. Ohta
NON. Oda
N. Oda
TYT. Yokoe
T. Yokoe
ATA. Tanaka
A. Tanaka
YYY. Yamamoto
Y. Yamamoto
MAM. Adachi
M. Adachi

18 November 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HIHideki Inoue
Hideki Inoue
KAKaho Akimoto
Kaho Akimoto
THTetsuya Homma
Tetsuya Homma
ATAkihiko Tanaka
Akihiko Tanaka
Hironori SagaraHironori Sagara
Hironori Sagara
Airway epithelium plays an important role as the first barrier from external pathogens, including bacteria, viruses, chemical substances, and allergic components. Airway epithelial cells also have pivotal roles as immunological coordinators of defense mechanisms to transfer signals to immunologic cells to eliminate external pathogens from airways. Impaired airway epithelium allows the pathogens to remain in the airway epithelium, which induces aberrant immunological reactions. Dysregulated functions of asthmatic airway epithelium have been reported in terms of impaired wound repair, fragile tight junctions, and excessive proliferation, leading to airway remodeling, which contributes to aberrant airway responses caused by external pathogens. To maintain airway epithelium integrity, a family of epidermal growth factor receptors (EGFR) have pivotal roles in mechanisms of cell growth, proliferation, and differentiation. There are extensive studies focusing on the relation between EGFR and asthma pathophysiology, which describe airway remodeling, airway hypermucus secretion, as well as immunological responses of airway inflammation. Furthermore, the second EGFR family member, erythroblastosis oncogene B2 (ErbB2), has been recognized to be involved with impaired wound recovery and epithelial differentiation in asthmatic airway epithelium. In this review, the roles of the EGFR family in asthmatic airway epithelium are focused on to elucidate the pathogenesis of airway epithelial dysfunction in asthma.

20 November 2014 in Respiratory Research
Verified
Journal Article
Open access
PDF file
ATAkihiko Tanaka
Akihiko Tanaka
MJMegumi Jinno
Megumi Jinno
KHKuniaki Hirai
Kuniaki Hirai
YMYoshito Miyata
Yoshito Miyata
HMHiroko Mizuma
Hiroko Mizuma
Hironori SagaraHironori Sagara
Hironori Sagara
Immunoglobulin (Ig) E is well-known to play a critical role in allergic diseases. We investigated the association between longitudinal change in total IgE level and the asthma control in patients with adult asthma. For this retrospective study, 154 patients with asthma aged 21–82 years were recruited from the allergy and pulmonary units of the Showa University Hospital. Data on longitudinal changes in IgE over the preceding 10 years were collected and logarithmically transformed. Associations between longitudinal change in IgE and clinical characteristics including asthma control test (ACT) score, asthma control, pulmonary function test, and antigen specific IgE, were assessed. Patients with increased IgE tended to have significantly higher mean age, more episodes of acute exacerbation within a year, lower ACT scores, and used oral corticosteroids more frequently than those with decreased or unchanged IgE. The prevalence of uncontrolled asthma was higher in patients with increased IgE than in those with decreased or unchanged IgE. Mean %FEV1 and FEV1% were lower in patients with increased IgE than in those with decreased or unchanged IgE. Moreover, the prevalence of Aspergillus-specific IgE was higher in patients with increased IgE than in those with decreased or unchanged IgE. These data suggest that a longitudinal increase in total IgE is associated with both poor asthma control and Aspergillus-specific IgE in patients with adult asthma.

26 February 2022 in Cells
Verified
Journal Article
Open access
PDF file
KAKoichi Ando
Koichi Ando
YFYosuke Fukuda
Yosuke Fukuda
ATAkihiko Tanaka
Akihiko Tanaka
Hironori SagaraHironori Sagara
Hironori Sagara
The anti-thymic stromal lymphopoietin antibody (tezepelumab) has therapeutical potential for inadequately controlled asthma. However, evidence comparing tezepelumab with other biologics is scarce. To address this issue, we performed a network meta-analysis to compare and rank the efficacy of five treatments (tezepelumab, dupilumab, benralizumab, mepolizumab, and placebo) in overall participants and in subgroups stratified by the thresholds of type 2 inflammatory biomarkers, including peripheral blood eosinophil count (PBEC) and fractional exhaled nitric oxide (FeNO). The primary endpoints were annualized exacerbation rate (AER) and any adverse events (AAEs). In the ranking assessment using surface under the cumulative ranking curve (SUCRA) of AER, tezepelumab ranked the highest overall and across subgroups (based on PBEC and FeNO level thresholds). A significant difference was observed between tezepelumab and dupilumab in the patient subgroup with PBEC < 150, and between tezepelumab and benralizumab in overall participants and the patient subgroup with PBEC ≥ 300 and ≥150, respectively. There was no significant difference in the incidence of AAEs in the overall participants between each pair of five treatment arms. These results provide a basis for the development of treatment strategies for asthma and may guide basic, clinical, or translational research.

1 September 2015 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
ATAkihiko Tanaka
Akihiko Tanaka
SSShintaro Suzuki
Shintaro Suzuki
SOShin Ohta
Shin Ohta
RMRyo Manabe
Ryo Manabe
HFHitomi Furukawa
Hitomi Furukawa
HSHironori Sagara
Hironori Sagara

23 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KAKoichi Ando
Koichi Ando
RMRyo Manabe
Ryo Manabe
YKYasunari Kishino
Yasunari Kishino
SKSojiro Kusumoto
Sojiro Kusumoto
TYToshimitsu Yamaoka
Toshimitsu Yamaoka
Hironori SagaraHironori Sagara
Hironori Sagara
To date, there have been no head-to-head randomized controlled trials (RCTs) comparing the safety and efficacy of lorlatinib and alectinib in anaplastic lymphoma kinase (ALK) rearrangement-positive (ALK-p) ALK-inhibitor‒naïve advanced non-small cell lung cancer (NSCLC). We performed a network meta-analysis comparing six treatment arms (lorlatinib, brigatinib, alectinib, ceritinib, crizotinib, and platinum-based chemotherapy) in overall participants and in Asian and non-Asian subgroups. Primary endpoints were progression-free survival (PFS), overall survival (OS), and grade 3 or higher adverse events (G3-AEs). There were no significant differences between lorlatinib and alectinib in overall participants for both PFS (hazard ratio [HR], 0.742; 95% credible interval [CrI], 0.466–1.180) and OS (HR, 1.180; 95% CrI, 0.590–2.354). In the Asian subgroup, there were no significant differences in PFS between lorlatinib and alectinib (HR, 1.423; 95% CrI, 0.748–2.708); however, in the non-Asian subgroup, PFS was significantly better with lorlatinib than with alectinib (HR, 0.388; 95% CrI, 0.195–0.769). The incidence of G3-AEs in overall participants was significantly higher with lorlatinib than with alectinib (risk ratio, 1.918; 95% CrI, 1.486–2.475). These results provide valuable information regarding the safety and efficacy of lorlatinib in ALK-p ALK-inhibitor‒naïve advanced NSCLC. Larger head-to-head RCTs are needed to validate the study results.